Pfizer enters Alnylam, Ionis' TTR turf with early approval for cardiomyopathy drug, carrying a $225K price tag
Pfizer is set to pull its weight in transthyretin-mediated amyloidosis, a field that has so far been Alnylam and Ionis’ turf.
Transthyretin (TTR) is a relatively abundant protein in the blood, which transports thyroxine and retinol. But it can become unstable and misfold — due to a genetic mutation or environmental factors — sparking an accumulation of toxic amyloid aggregates in the heart or peripheral nerves.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.